{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:51:55Z","timestamp":1785912715312,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016170","name":"Japan Blood Products Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009337","name":"Saitama Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaut.2026.103588","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:40:12Z","timestamp":1781210412000},"page":"103588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term effectiveness, safety, and cost-effectiveness of intravenous immunoglobulin for generalized myasthenia gravis in an era of molecular targeted drugs: Insights from Japanese post-marketing surveillance"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-4574","authenticated-orcid":false,"given":"Shigeaki","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minami","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Wakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2026.103588_bib1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2026.103588_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274161","article-title":"Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018","volume":"17","author":"Yoshikawa","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2026.103588_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cen3.12731","article-title":"Japan MG registry: chronological surveys over 10 years","volume":"14","author":"Suzuki","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.jaut.2026.103588_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2026.103588_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.jaut.2026.103588_bib6","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2026.103588_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.jaut.2026.103588_bib8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2026.103588_bib9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2026.103588_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jaut.2026.103588_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2026.103588_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2026.103588_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.jaut.2026.103588_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2026.103588_bib16","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2026.103588_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2026.103588_bib18","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2026.103588_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaut.2026.103588_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211001995","article-title":"Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance","volume":"14","author":"Murai","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jaut.2026.103588_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2025.2490063","article-title":"Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance","volume":"25","author":"Teranishi","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jaut.2026.103588_bib22","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1186\/s12913-022-08954-8","article-title":"A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study","volume":"22","author":"Zagni","year":"2022","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.jaut.2026.103588_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13760-016-0689-z","article-title":"A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients","volume":"117","author":"Alipour-Faz","year":"2017","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jaut.2026.103588_bib25","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s13311-021-01108-4","article-title":"Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy","volume":"18","author":"Dalakas","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jaut.2026.103588_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jaut.2026.103588_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/22143602241305511","article-title":"Rozanolixizumab in generalized myasthenia gravis: pooled analysis of the Phase 3 MycarinG study and two open-label extensions","volume":"12","author":"Bril","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.jaut.2026.103588_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaut.2026.103588_bib29","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1159\/000529110","article-title":"Adverse reactions associated with intravenous immunoglobulin administration in the treatment of neurological disorders: a systematic review","volume":"184","author":"Jiang","year":"2023","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.jaut.2026.103588_bib30","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.neurol.2021.10.004","article-title":"Immunoglobulin shortage: practice modifications and clinical outcomes in a reference centre","volume":"178","author":"N'Kaoua","year":"2022","journal-title":"Rev. Neurol. (Paris)"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841126000661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:27:35Z","timestamp":1785911255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841126000661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"alternative-id":["S0896841126000661"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103588","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effectiveness, safety, and cost-effectiveness of intravenous immunoglobulin for generalized myasthenia gravis in an era of molecular targeted drugs: Insights from Japanese post-marketing surveillance","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2026.103588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103588"}}